Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
DEPO's Cash to Debt is ranked higher than
95% of the 773 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.62 vs. DEPO: No Debt )
DEPO' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: No Debt

Equity to Asset 0.34
DEPO's Equity to Asset is ranked lower than
51% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. DEPO: 0.34 )
DEPO' s 10-Year Equity to Asset Range
Min: -2.63   Max: 0.97
Current: 0.34

-2.63
0.97
Interest Coverage 1.73
DEPO's Interest Coverage is ranked lower than
55% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. DEPO: 1.73 )
DEPO' s 10-Year Interest Coverage Range
Min: 1.73   Max: 9999.99
Current: 1.73

1.73
9999.99
F-Score: 5
Z-Score: 2.16
M-Score: 0.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 6.94
DEPO's Operating margin (%) is ranked higher than
70% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. DEPO: 6.94 )
DEPO' s 10-Year Operating margin (%) Range
Min: -12972.91   Max: 72.49
Current: 6.94

-12972.91
72.49
Net-margin (%) 32.27
DEPO's Net-margin (%) is ranked higher than
98% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. DEPO: 32.27 )
DEPO' s 10-Year Net-margin (%) Range
Min: -14964.35   Max: 75.05
Current: 32.27

-14964.35
75.05
ROE (%) 31.52
DEPO's ROE (%) is ranked higher than
98% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. DEPO: 31.52 )
DEPO' s 10-Year ROE (%) Range
Min: -361.88   Max: 108.13
Current: 31.52

-361.88
108.13
ROA (%) 8.52
DEPO's ROA (%) is ranked higher than
88% of the 748 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. DEPO: 8.52 )
DEPO' s 10-Year ROA (%) Range
Min: -201.21   Max: 61.03
Current: 8.52

-201.21
61.03
ROC (Joel Greenblatt) (%) 111.71
DEPO's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. DEPO: 111.71 )
DEPO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2343.1   Max: 6607.29
Current: 111.71

-2343.1
6607.29
Revenue Growth (%) 15.60
DEPO's Revenue Growth (%) is ranked higher than
81% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. DEPO: 15.60 )
DEPO' s 10-Year Revenue Growth (%) Range
Min: -69.7   Max: 420.5
Current: 15.6

-69.7
420.5
EBITDA Growth (%) 46.00
DEPO's EBITDA Growth (%) is ranked higher than
94% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. DEPO: 46.00 )
DEPO' s 10-Year EBITDA Growth (%) Range
Min: -55.8   Max: 84.2
Current: 46

-55.8
84.2
EPS Growth (%) 120.50
DEPO's EPS Growth (%) is ranked higher than
98% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. DEPO: 120.50 )
DEPO' s 10-Year EPS Growth (%) Range
Min: -59.5   Max: 180.9
Current: 120.5

-59.5
180.9
» DEPO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

DEPO Guru Trades in Q1 2013

Steven Cohen 8,395 sh (+1130.94%)
Paul Tudor Jones 43,000 sh (+129.95%)
» More
Q2 2013

DEPO Guru Trades in Q2 2013

Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q4 2013

DEPO Guru Trades in Q4 2013

Jim Simons 129,338 sh (New)
Paul Tudor Jones 19,853 sh (New)
Steven Cohen 1,867,300 sh (New)
» More
Q1 2014

DEPO Guru Trades in Q1 2014

Paul Tudor Jones 63,632 sh (+220.52%)
Jim Simons Sold Out
Steven Cohen 17,403 sh (-99.07%)
» More
» Details

Insider Trades

Latest Guru Trades with DEPO

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2012-06-30 Sold Out 0.01%$4.97 - $6.6 $ 10.6988%0
Daniel Loeb 2011-09-30 Sold Out 0.6154%$5 - $8.74 $ 10.6961%0
Joel Greenblatt 2011-09-30 Add 48.97%$5 - $8.74 $ 10.6961%15244
Daniel Loeb 2011-06-30 Reduce -34.52%0.46%$7.78 - $9.9 $ 10.6927%2030000
Joel Greenblatt 2011-06-30 New Buy0.01%$7.78 - $9.9 $ 10.6927%10233
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 9.30
DEPO's P/E(ttm) is ranked higher than
97% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.40 vs. DEPO: 9.30 )
DEPO' s 10-Year P/E(ttm) Range
Min: 2.36   Max: 121.85
Current: 9.3

2.36
121.85
P/B 3.80
DEPO's P/B is ranked higher than
62% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. DEPO: 3.80 )
DEPO' s 10-Year P/B Range
Min: 2   Max: 48.18
Current: 3.8

2
48.18
P/S 3.38
DEPO's P/S is ranked higher than
68% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. DEPO: 3.38 )
DEPO' s 10-Year P/S Range
Min: 1.38   Max: 530
Current: 3.38

1.38
530
EV-to-EBIT 8.70
DEPO's EV-to-EBIT is ranked higher than
95% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.81 vs. DEPO: 8.70 )
DEPO' s 10-Year EV-to-EBIT Range
Min: 0.4   Max: 130
Current: 8.7

0.4
130
Shiller P/E 50.60
DEPO's Shiller P/E is ranked higher than
80% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. DEPO: 50.60 )
DEPO' s 10-Year Shiller P/E Range
Min: 21.62   Max: 123.75
Current: 50.6

21.62
123.75
Current Ratio 2.64
DEPO's Current Ratio is ranked higher than
73% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. DEPO: 2.64 )
DEPO' s 10-Year Current Ratio Range
Min: 0.57   Max: 56
Current: 2.64

0.57
56
Quick Ratio 2.56
DEPO's Quick Ratio is ranked higher than
77% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. DEPO: 2.56 )
DEPO' s 10-Year Quick Ratio Range
Min: 0.57   Max: 56
Current: 2.56

0.57
56

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.50
DEPO's Price/Tangible Book is ranked higher than
58% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. DEPO: 7.50 )
DEPO' s 10-Year Price/Tangible Book Range
Min: 2.54   Max: 87
Current: 7.5

2.54
87
Price/DCF (Projected) 12.70
DEPO's Price/DCF (Projected) is ranked higher than
76% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. DEPO: 12.70 )
DEPO' s 10-Year Price/DCF (Projected) Range
Min: 1.18   Max: 335
Current: 12.7

1.18
335
Price/Median PS Value 0.80
DEPO's Price/Median PS Value is ranked higher than
86% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. DEPO: 0.80 )
DEPO' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 109.25
Current: 0.8

0.36
109.25
Price/Graham Number 1.70
DEPO's Price/Graham Number is ranked higher than
84% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. DEPO: 1.70 )
DEPO' s 10-Year Price/Graham Number Range
Min: 0.61   Max: 7.48
Current: 1.7

0.61
7.48
Earnings Yield (Greenblatt) 12.00
DEPO's Earnings Yield (Greenblatt) is ranked higher than
90% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.90 vs. DEPO: 12.00 )
DEPO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 251.9
Current: 12

0.8
251.9
Forward Rate of Return (Yacktman) 0.51
DEPO's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. DEPO: 0.51 )
DEPO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -27.2   Max: 5.3
Current: 0.51

-27.2
5.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DPO.Germany
Depomed, Inc. was incorporated in the State of California on August 7, 1995. The Company is a specialty pharmaceutical company that focuses on pain and other conditions and diseases of the central nervous system. Its products line encompasses Gralise, Zipsor, Glumetza, Janumet XR, and Proquin XR, among others. The core products comprises of Gralise, a once-daily product for the management of postherpetic neuralgia, and Zipsor liquid filled capsules, a product for the treatment of mild to moderate acute pain. It also has a portfolio of royalty and milestone producing assets based on its proprietary drug delivery technologies. A part of it is Glumetza, a once-daily treatment for adults with type 2 diabetes which is licensed and commercialized in the United States. It also has license and development arrangements for Acuform gastroretentive drug delivery technology with Covidien, Ltd., Boehringer Ingelheim International GMBH, Ironwood Pharmaceuticals, Inc., Merck & Co., Inc., Janssen Pharmaceutica N.V. and Janssen Pharmaceuticals, Inc. Further, it has two product candidates in clinical development, Serada and DM-1992. The Company derives revenues from the sale of its products, and from license fees, milestones and royalties earned on license agreements, as well as collaborative arrangements.
» More Articles for DEPO

Headlines

Articles On GuruFocus.com
5 Healthcare Picks for 2012 Mar 21 2012 
Depomed Inc. Reports Operating Results (10-K) Mar 16 2011 
Depomed Inc. Reports Operating Results (10-Q) Aug 06 2010 
Depomed Inc. Reports Operating Results (10-Q) May 04 2010 
Depomed Inc. Reports Operating Results (10-Q) Aug 07 2009 
Depomed Reports Second Quarter 2009 Financial Results Jul 30 2009 
Depomed Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 Jul 25 2014
DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events Jul 17 2014
Depomed Announces District Court Order in ANDA Litigation Jul 17 2014
Depomed appoints Srinivas Rao as Chief Medical Officer Jul 16 2014
Depomed Announces Appointment of Srinivas G. Rao, MD, PhD, as Chief Medical Officer Jul 16 2014
Coverage initiated on DepoMed by WallachBeth Jul 10 2014
Immune Pharma: A Top-Pick Based On Pipeline And Valuation Jul 09 2014
Martin Marietta Materials Set to Join the S&P 500; United States Steel Corp. Set to Join the S&P... Jun 27 2014
DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 20 2014
Exclusive: Steven Burrill Removed From Control Of Venture Fund For Unauthorized Payments Jun 18 2014
Depomed To Present AT JMP Securities 2014 Healthcare Conference Jun 18 2014
Depomed to Present at Wells Fargo 2014 Healthcare Conference Jun 10 2014
Mallinckrodt's NDA accepted by FDA, triggering $5M payment to Depomed May 28 2014
Mallinckrodt New Drug Application For MNK-155 Accepted For Review By FDA May 28 2014
Depomed To Present At Jefferies 2014 Global Healthcare Conference May 27 2014
DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to... May 23 2014
Nasdaq stocks posting largest percentage increases May 20 2014
DEPOMED INC Financials May 16 2014
Perilous Reversal Stock: DepoMed (DEPO) May 13 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide